Citation: | LI Wen-dong, WANG Jing, ZHANG Yan-qin, WANG Hai-sheng, GAO Ying-ying. The study of correlation between serum anti-phospholipase A2 receptor antibody and clinicopathology feature and the efficacy in patients with idiopathic membranous nephropathy[J]. Journal of Clinical Nephrology, 2020, 20(12): 942-945. DOI: 10.3969/j.issn.1671-2390.2020.12.002 |
[1] |
Floege J,Barbour SJ,Catran DC,et al.Management and treatment of glomerular diseases(part 1):conclusions from a Kidney Disease:Improving Global Outcomes (KDIGO) Controversies Conference[J].Kidney Int,2019,95(2):268-280.DOI: 10.1016/j.kint.2018.10.018.
|
[2] |
陈崴,余学清.中国成人肾病综合征免疫抑制治疗专家共识[J].中华肾脏病杂志,2014,30(6):467-474.DOI: 10.3760/cma.j.issn.1001-7097.2014.06.014.
|
[3] |
李强,张蓓茹,何平,等.血清PLA2R抗体检测在特发性膜性肾病临床及治疗反应评价中的应用(附250例报告)[J].中国实用内科杂志,2018,38(12):1173-1176.DOI: 10.19538/j.nk2018120116.
|
[4] |
BeckLH Jr.PLA2R and THSD7A:disparate paths to the same disease?[J].J Am Soc Nephrol,2017,28(9):2579-2589.DOI: 10.1681/ASN.2017020178.
|
[5] |
Beck LH Jr,Bonegio RG,Lambeau G,et al.M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J].N Engl J Med,2009,361(1):11-21.DOI: 10.1056/NEJMoa0810457.
|
[6] |
张亚琪,郝亚宁,冯学亮,等.单中心特发性膜性肾病发病趋势及与血清PLA2R抗体的相关性分析[J].中华肾脏病杂志,2016,32(9):647-652.DOI: 10.3760/cma.j.issn.1001-7097.2016.09.002.
|
[7] |
庄永泽,刘敏.血清抗PLA2R抗体水平与成人特发性膜性肾病临床病理的相关性研究[J].中国中西医结合肾病杂志,2019,20(12):1068-1072.DOI: 10.3969/j.issn.1009-587x.2019.12.011.
|
[8] |
Kim YG,Chai YW,Kim SY,et al.Anti-phospholipase A2 receptorantibody as prognostic indicator in idiopathic membranous nephropathy[J].Am J Nephrol,2015,42(3):250-257.DOI: 10.1159/000440983.
|
[9] |
Radices A,Trezzi B,Maggiore U,et al.Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN)[J].Autoimmune Rev,2016,15(2):146-154.DOI: 10.1016/j.autrev.2015.10.004.
|
[10] |
Gerry MJ,Vanhille P,Roneo P,et al.Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy[J].Kidney Int,2016,89(6):1399.DOI: 10.1016/j.hint.2015.11.032.
|
[11] |
Hoxha E,Tiele I,Zahner G,et al.Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy[J].J Am Soc Nephrol,2014,25(6):1357-1366.DOI: 10.1681/ASN.2013040430.
|
[12] |
Ruggenenti P,Debiec H,Ruggero B,et al.Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy[J].J Am Soc Nephrol,2015,26(10):2545-2558.DOI: 10.1681/ASN.2014070640.
|
[13] |
Dahan K,Debiec H,Plaister E,et al.Rituximab for severe membranous nephropathy:a 6-month trial with extended follow-up[J].J Am Soc Nephrol,2017,28(1):348-358.DOI: 10.1681/ASN.2016040449.
|
1. |
王欢,山晓微,张德伟. 血清IgG/C3水平对磷脂酶A2受体抗体阴性的糖尿病伴蛋白尿患者膜性肾病的预测价值. 临床肾脏病杂志. 2024(12): 977-982 .
![]() | |
2. |
李俊,王红军,吴新萍. 活血祛浊益气方缓解膜性肾病阳虚证临床观察. 吉林中医药. 2022(08): 936-939 .
![]() | |
3. |
张承宁,段俗言,袁杨刚,朱敬凤,黄智敏,孙彬,张波,毛慧娟,邢昌赢. 影响他克莫司治疗特发性膜性肾病疗效的相关因素及其预测价值分析. 临床肾脏病杂志. 2022(10): 807-813 .
![]() |